Braasch Biotech Bolsters Intellectual Property with Patent Acceptance in the Philippines
Braasch Biotech LLC continues patent portfolio expansion with new issue in the Philippines. Novel technologies allow safe enhancement of livestock productivity by use of vaccination rather than exogenous pharmaceuticals.
Garretson, SD, January 15, 2015 --(PR.com)-- Braasch Biotech LLC, a biopharmaceutical company developing and commercializing anti-somatostatin vaccines, today announced that it has received a Notice of Acceptance from the Republic of the Philippines Patent Office for a patent covering the use of Braasch’s product candidate, JH14-Somatovac®. Braasch vaccines are directed toward the archetype counter-regulatory hormone somatostatin. The effects of attenuating somatostatin levels by Braasch vaccines have resulted in increased efficiencies both in milk yields in dairy cows and lean meat production in pigs.
The global demand for animal protein (such as meat and milk proteins) continues to increase rapidly and is expected to double by 2050 (FAO). Increasing world population, emerging economies, increasing urbanization and other lesser factors, drives this demand. New initiatives will be required to enhance the sustainability of animal protein production without proportionally increasing land for agriculture.
“Braasch vaccines allow the vaccinated animal to achieve their own endogenous ability to be more productive,” stated Jeralyn Haffer, Braasch Biotech’s CEO. “Improving the production of farmed animals without the use of exogenous hormones, such as bovine somatotropin (rBst), antibiotics or pharmaceutical growth promoters is not only safe for the animal, but also the environment and human consumers. Our technologies aim to help provide an increasing supply of high quality protein that the world’s expanding population demands.”
Braasch Biotech’s current livestock enhancement portfolio already includes patents in the United States, Europe, Mexico, New Zealand, Israel, South Africa, Australia, Japan and Russia. Braasch is also pursuing patent applications in multiple jurisdictions in Latin America and Asia.
About Braasch Biotech
Braasch Biotech is pioneering a new field of metabolic and therapeutic vaccine approaches utilizing its Somatovac® technologies. The company has received numerous US and International patents for vaccine usage in obesity and livestock productivity. Braasch Biotech is a privately held biopharmaceutical company with corporate offices in South Dakota.
For more information on Braasch Biotech, please email info@braaschbiotech.com or visit www.braaschbiotech.com
The global demand for animal protein (such as meat and milk proteins) continues to increase rapidly and is expected to double by 2050 (FAO). Increasing world population, emerging economies, increasing urbanization and other lesser factors, drives this demand. New initiatives will be required to enhance the sustainability of animal protein production without proportionally increasing land for agriculture.
“Braasch vaccines allow the vaccinated animal to achieve their own endogenous ability to be more productive,” stated Jeralyn Haffer, Braasch Biotech’s CEO. “Improving the production of farmed animals without the use of exogenous hormones, such as bovine somatotropin (rBst), antibiotics or pharmaceutical growth promoters is not only safe for the animal, but also the environment and human consumers. Our technologies aim to help provide an increasing supply of high quality protein that the world’s expanding population demands.”
Braasch Biotech’s current livestock enhancement portfolio already includes patents in the United States, Europe, Mexico, New Zealand, Israel, South Africa, Australia, Japan and Russia. Braasch is also pursuing patent applications in multiple jurisdictions in Latin America and Asia.
About Braasch Biotech
Braasch Biotech is pioneering a new field of metabolic and therapeutic vaccine approaches utilizing its Somatovac® technologies. The company has received numerous US and International patents for vaccine usage in obesity and livestock productivity. Braasch Biotech is a privately held biopharmaceutical company with corporate offices in South Dakota.
For more information on Braasch Biotech, please email info@braaschbiotech.com or visit www.braaschbiotech.com
Contact
Braasch Biotech LLC
Keith Haffer
605-376-8756
www.braaschbiotech.com
Keith Haffer
605-376-8756
www.braaschbiotech.com
Contact
Categories